4.4 Article

Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose

Journal

JOURNAL OF CARDIOVASCULAR COMPUTED TOMOGRAPHY
Volume 11, Issue 5, Pages 373-382

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcct.2017.08.005

Keywords

Coronary computed tomography angiography; Functional testing; Chest pain; Coronary artery disease

Funding

  1. National Heart, Lung, and Blood Institute [R01HL098237, R01HL098236, R01HL098305, R01HL098235, R01HL109711]
  2. American Roentgen Ray Society Scholarship
  3. Siemens Healthcare
  4. GE Healthcare
  5. Philips Healthcare
  6. Toshiba America Medical Systems
  7. Eli Lilly
  8. Bristol-Myers Squibb
  9. Gilead Sciences
  10. AGA Medical
  11. Merck
  12. Oxygen Biotherapeutics
  13. AstraZeneca
  14. Medtronic
  15. CardioDx
  16. St. Jude Medical
  17. HeartFlow
  18. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL098236, R01HL098235, R01HL109711, R01HL098237, R01HL098305] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Background: Coronary computed tomography angiography (CTA) and functional testing strategies for stable chest pain yield similar outcomes; one aspect that may guide test choice is safety. Methods: We compared test safety (test complications, incidental findings, and effective radiation dose) between CTA and functional testing as-tested in PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain). In the subgroup whose physicians intended nuclear stress over other functional tests if randomized to the functional arm, we compared radiation dose of CTA versus nuclear stress and identified characteristics associated with dose. Results: Of 9470 patients, none had major and <1% had minor complications (CTA: 0.8% [37/4633] vs. functional: 0.6% [27/4837]). CTA identified more incidental findings (11.6% [539/46331 vs. 0.7% [34/4837], p < 0.001), most commonly pulmonary nodules (9.4%, 437/4633). CTA had similar 90-day cumulative radiation dose to functional testing. However, in the subgroup whose physicians intended nuclear stress (CTA 3147; nuclear 3203), CTA had lower median index test (8.8 vs. 12.6 mSv, p < 0.001) and 90-day cumulative (11.6 vs. 13.1 mSv, p < 0.001) dose, independent of patient characteristics. The lowest nuclear doses employed 1-day Tc-99m protocols (12.2 mSv). The lowest CTA doses were at sites performing >= 500 CTAs/year (6.9 mSv) and with advanced (latest available) CT scanners (5.5 mSv). Conclusion: Complications were negligibly rare for both CTA and functional testing. CTA detects more incidental findings. Compared to nuclear stress testing, CTA's lower radiation dose, independent of patient characteristics, makes it an attractive test choice. Radiation dose varies with imaging protocol, indicating opportunities to further reduce dose. (ClinicalTrials.gov number, NCT01174550). (C) 2017 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available